Comparing the current results to its competitors, Dianthus Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 294.3 % year on year. The sales growth was above Dianthus Therapeutics Inc 's competitors' average revenue growth of 5.14 %, achieved in the same quarter.
Dianthus Therapeutics Inc , slower than the average decrease reported by the company's competitors of -72.62 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -72.62 %
Dianthus Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes pharmaceutical and biotechnology companies, academic institutions, and government agencies. One competitor mentioned is argenx, which is developing empasiprubart (ARGX-117), an intravenous C2 inhibitor currently in a Phase 3 clinical trial. Competitors often possess greater financial, technical, and human resources, as well as more experience in drug discovery, development, regulatory approvals, and commercialization. Mergers and acquisitions may consolidate resources among fewer competitors, potentially enhancing their success in regulatory approval and market acceptance.
September 4, 2024
Dianthus Therapeutics Inc. (NASDAQ: DNTH), a promising player in the biopharmaceutical sector, is gearing up to participate in three significant healthcare investor conferences this September. As the company continues to push the boundaries of research and development in therapeutics, these engagements offer a crucial platform to connect with investors and share insights on its ongoing projects and future outlook.As of the writing of this article, Dianthus Therapeutics share price stands at $27.65, reflecting the market s robust interest in its potential. The company specializes in developing innovative therapies for patients with serious diseases, using cutting-edge techniques and a skilled team of profess...
June 12, 2024
Multifocal Motor Neuropathy (MMN) is a debilitating neurological disorder characterized by muscle weakness and atrophy, resulting from damage to the motor nerves. Despite being a rare condition, the impact on patients quality of life is significant. Currently, there are limited treatment options available for MMN, emphasizing the need for effective therapeutics. In this regard, Dianthus Therapeutics has recently received FDA clearance to initiate Phase 2 trials of DNTH103, raising hopes for potential breakthroughs in MMN management.DNTH103: A Novel Treatment ApproachDNTH103 is an innovative therapeutic candidate developed by Dianthus Therapeutics, targeting the underlying pathology of MMN. This agent focuse...
Publicly Traded Peers of Dianthus Therapeutics Inc
Viatris Inc Share Performance
+8.48%
This Quarter
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Sources:
Dianthus Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dianthus Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
